메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

With Child Deaths Projected to Rise for the First Time in a Century, Gates Foundation and Mohamed Bin Zayed Foundation for Humanity Urge Action as World Faces Critical Turning Point

[ 메디채널 김갑성 기자 ] At Goalkeepers Abu Dhabi, global leaders outline a path to improve and save the lives of millions of children through lifesaving innovation and renewed investment Partners announce $1.9 billion to advance polio eradication Event held in partnership with the Mohamed bin Zayed Foundation for Humanity highlights urgency, honors leadership, and showcases champions advancing progress despite historic global funding cuts ABU DHABI, UAE, Dec. 9, 2025 -- At Goalkeepers Abu Dhabi, leaders from government, philanthropy, business, and civil society issued a unified
- 김갑성 기자
- 2025-12-09 03:14
EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

PROVIDENCE, R.I., Dec. 9, 2025 -- EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publication of a study titled "Immunogenicity Risk Assessment of Peptide-Related Impurities Identified in Generic Teriparatide Products." The study uses a series of different tools to evaluate whether peptide-related impurities may influence unwanted immune responses in generic teriparatide (TPT)—an important consideration for ensuring the safety and comparability of generic peptide drugs. Teriparatide, a rec
- 김갑성 기자
- 2025-12-09 03:11
Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK, Dec. 8, 2025 -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated mean
- 김갑성 기자
- 2025-12-09 03:05
DAR GLOBALとART DISTRICT REAL ESTATE DEVELOPMENT、マスカットの海洋、芸術、デジタル地区「MAD」を発表

[ 메디채널 황정호 기자 ] マスカット（オマーン）, 2025年12月8日 -- ロンドン証券取引所上場の高級不動産開発会社であるDar Global（LSE: DAR）は、Art District Real Estate Developmentとの提携により、本日、マスカット海洋、芸術、デジタル地区「MAD」の立ち上げと開発に向けた協業開始を発表しました。これは、海辺の生活、高級ホスピタリティ、文化主導型企業、未来志向の金融・デジタル産業を統合した革新的な新たな沿岸地域です。オマーンの美しい海岸線に沿って位置する「MAD」プロジェクトは、総開発面積150万平方メートル以上、全開発フェーズにおける総開発価値は約16億オマーン・リアル（42億米ドル）に上り、12年以上にわたる開発計画となります。海を望む居住空間、ラグジュアリーホスピタリティ、文化的表現、そして未来の金融・デジタル産業を統合した単一のエコシステムを構築することで、オマーン・スルタン国の国際的地位向上を目指します。複合型都市として構想された「MAD」は、高級住宅コミュニティ、文化施設、世界水準のマリーナ、厳選された小売店舗、次世代金融・ビジネスパーク、プレミアムホテルを集結させます。この地区は、富裕層旅行者、グローバル投資家、アートコレクター、テック起業家、クリエ
- 황정호 기자
- 2025-12-09 00:34
Moutai Cultural Exhibition Ignites U.S. Audience with Immersive Journey Through a Century of Cultural Heritage

SAN FRANCISCO, Dec. 9, 2025 -- From December 7 to 8, Kweichow Moutai celebrated a dual milestone - the 110th anniversary of its award-winning debut at the 1915 Panama-Pacific International Exposition and the 10th anniversary of San Francisco Moutai Day - through a dynamic series of events that captivated local attendees. By blending an immersive cultural exhibition with the elegant "Moutai Night" gala dinner, the celebration offered guests a multifaceted experience rich in history, culture, and curated tastings. The events drew leaders from political, business, and cu
- 김장윤(JASON KIM) 기자
- 2025-12-09 00:13
GIGABYTEの確かな信頼性を体現したAORUS PRIME 5デスクトップ・システムが発売開始

[ 메디채널 김장윤(JASON KIM) 기자 ] 台北、2025年12月9日 -- 世界有数のコンピューター・ブランドであるGIGABYTEは、AORUS PRIME 5が正式に発売されたことを発表しました。この高性能デスクトップ・システムは、フラッグシップグレードのハードウェアと、GIGABYTE独自の冷却技術革新および高度なファン・テクノロジーを組み合わせた新しいアーキテクチャに基づいて構築されています。AORUS PRIME 5は、ゲームやマルチタスクに優れた速度と長期的な信頼性を提供するように設計されており、パワー、精度、デザインをシンプルなプラグ・アンド・プレイと融合しています。 AORUS PRIME 5は、マルチコアと次世代AIパフォーマンスを実現するAMD Ryzen™ 7 9800X3DプロセッサとNVIDIA® GeForce RTX™ 5080グラフィック・カードを搭載可能。さらに、2TB SSDと32GBの高速RGBメモリを含むGIGABYTE製品のみで構築された設計により、超高速の応答性とシームレスなマルチタスクを実現します。この構成は、実証済みの安定性というGIGABYTE のDNAを体現しており、その優れた性能は、完全に統合された冷却ソリューションにも反映されています。新しいHawk F
- 김장윤(JASON KIM) 기자
- 2025-12-09 00:00
Convergen Secures $10 Million Seed Funding to Advance TrimTAC Platform for Neurodegeneration & beyond

SUZHOU, China, Dec. 8, 2025 -- Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $10 million Seed financing round. The round was invested by Qiming Venture Partners, a leading global venture capital firm focused on life sciences and healthcare innovation. Funds from the financing will accelerate the development of Convergen's proprietary TrimTAC platform—next-generation bifunctional degraders leveraging the E3 ubiquitin ligase TRIM21—and advance its early
- 김갑성 기자
- 2025-12-08 23:00
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes –– Favorable safety profile with no treatment-related serious adverse events – LEHI, Utah, Dec. 8, 2025 -- Halia Therapeutics, a clinical-stage biopharmaceutical company, today presented new clinical data from its Phase 2a study of ofirnoflast (HT-6184) at the 67th American Society of Hematology (ASH) Annual Meeting. The data show that ofirnoflast, a first-
- 김갑성 기자
- 2025-12-08 22:22
AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C Reports Unaudited Financial Results for the Six Months Ended June 30, 2025

DUBAI, UAE, Dec. 8, 2025 -- AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C, (the "Company") (Nasdaq: AHMA), a United Arabic Emirates-based MICE (meetings, incentives, conferences, and exhibitions) and tourism services provider, today announced its unaudited financial results for the six months ended June 30, 2025. Financial Highlights for the Six Months Ended June 30, 2025 Revenue increased by 14% to US$9.7 million for the six months ended June 30, 2025, from US$8.5 million for the six months ended June 30, 2024. MICE management solution services revenue increased by 3
- 황정호 기자
- 2025-12-08 22:15
ALR TECHNOLOGIES TO RELAUNCH THE GLUCURVE PET CGM IN JANUARY 2026

SINGAPORE, Dec. 8, 2025 -- ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces the successful completion of internal manufacturing testing on the GluCurve Pet CGM ("GluCurve") showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. GluCurve is the first and only diabetic monitoring system built specifically for veterinary use on cats and dogs. A pet-friendly Continuous Glucose Monitor
- 김갑성 기자
- 2025-12-08 22:14

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 07시 00분